0
We're unable to sign you in at this time. Please try again in a few minutes.
Retry
We were able to sign you in, but your subscription(s) could not be found. Please try again in a few minutes.
Retry
There may be a problem with your account. Please contact the AMA Service Center to resolve this issue.
Contact the AMA Service Center:
Telephone: 1 (800) 262-2350 or 1 (312) 670-7827  *   Email: subscriptions@jamanetwork.com
Error Message ......


Basic View | Expanded View
 Showing 1-20 of 57 Articles

Suspected non-Alzheimer pathophysiology (SNAP) is a biomarker-based concept suggested as a complement to the new National Institute on Aging–Alzheimer Association (NIA-AA) research criteria of preclinical Alzheimer disease (AD).1 The NIA-AA classifies individuals with preclinical AD into 1 of the following 3 stages: biomarker evidence of β-amyloid (Aβ) ...

Editorial 
Clifford R. Jack Jr, MD

In this issue of JAMA Neurology, Gordon and colleagues1 from Washington University publish a well-done study on an important and topical subject. The investigators used the 2-class Alzheimer disease (AD) biomarker classification scheme that arises when combining biomarker staging for preclinical AD recommended by the National ...

Original Investigation  FREE
Elizabeth C. Mormino, PhD; Kathryn V. Papp, PhD; Dorene M. Rentz, PsyD; Aaron P. Schultz, PhD; Molly LaPoint, BS; Rebecca Amariglio, PhD; Bernard Hanseeuw, MD, PhD; Gad A. Marshall, MD; Trey Hedden, PhD; Keith A. Johnson, MD; Reisa A. Sperling, MD
Includes: Supplemental Content

Importance  A substantial proportion of clinically normal (CN) older individuals are classified as having suspected non–Alzheimer disease pathophysiology (SNAP), defined as biomarker negative for β-amyloid (Aβ−) but positive for neurodegeneration (ND+). The etiology of SNAP in this population remains unclear.

Objective  To determine whether CN individuals ...

Original Investigation 
Brian A. Gordon, PhD; Tyler Blazey, BS; Yi Su, PhD; Anne M. Fagan, PhD; David M. Holtzman, MD; John C. Morris, MD; Tammie L. S. Benzinger, MD, PhD
Includes: Supplemental Content

Importance  Preclinical Alzheimer disease (AD) can be staged using a 2-factor model denoting the presence or absence of β-amyloid (Aβ+/−) and neurodegeneration (ND+/−). The association of these stages with longitudinal biomarker outcomes is unknown.

Objective  To examine whether longitudinal Aβ accumulation and hippocampal atrophy differ based ...

Comment & Response 
Kimberly N. Grelli, MD; Melissa C. Gindville, MS; Lori C. Jordan, MD, PhD

In Reply We thank Goh and Sivakumaran for their interest in and comments on our article,1 which was a retrospective study of blood pressure, blood glucose, and fever and their associations with outcome after arterial ischemic stroke (AIS) in children. Although we did not find a significant ...

Comment & Response 
En Lin Goh, BSc; Prasanthi Sivakumaran, BSc

To the Editor We thank Grelli et al1 for their study investigating the factors associated with neurological outcome following childhood stroke. The authors1 reported an association between hyperglycemia and poor neurological outcome in their cohort.

Editorial 
Andrew J. Cole, MD

There is general agreement among neurologists, emergency physicians, and intensivists that status epilepticus is a medical emergency; that the longer status goes on, the more difficult it is to stop; and that as the status moves up the severity spectrum from simple status to refractory status requiring treatment ...

Original Investigation 
Sara Hocker, MD; Elanagan Nagarajan, MD; Alejandro A. Rabinstein, MD; Dennis Hanson, MA; Jeffrey W. Britton, MD

Importance  Prolonged seizures in super-refractory status epilepticus (SRSE) have been shown to cause neuronal death and reorganization, and visual inspection in individual case studies has demonstrated progressive cortical and subcortical atrophy. At present, magnetic resonance imaging (MRI) studies that evaluate brain atrophy in SRSE are lacking.

Objectives...

Original Investigation 
Giuseppe Tosto, MD, PhD; Thomas D. Bird, MD; David A. Bennett, MD; Bradley F. Boeve, MD; Adam M. Brickman, PhD; Carlos Cruchaga, PhD; Kelley Faber, MS; Tatiana M. Foroud, PhD; Martin Farlow, MD; Alison M. Goate, DPhil; Neill R. Graff-Radford, MD; Rafael Lantigua, MD; Jennifer Manly, PhD; Ruth Ottman, PhD; Roger Rosenberg, MD; Daniel J. Schaid, PhD; Nicole Schupf, PhD; Yaakov Stern, PhD; Robert A. Sweet, MD; Richard Mayeux, MD, MSc; for the National Institute on Aging Late-Onset Alzheimer Disease/National Cell Repository for Alzheimer Disease (NIA-LOAD/NCRAD) Family Study Group
Includes: Supplemental Content

Importance  The contribution of cardiovascular disease (CV) and cerebrovascular disease to the risk for late-onset Alzheimer disease (LOAD) has been long debated. Investigations have shown that antecedent CV risk factors increase the risk for LOAD, although other investigations have failed to validate this association.

Objective  To ...

Observation 
Volker Behrendt, MD; Christos Krogias, MD; Anke Reinacher-Schick, MD; Ralf Gold, MD; Ingo Kleiter, MD

This case series describes 2 women with anti-N-methyl-d-aspartate receptor (anti-NMDAR) encephalitis whose disease remitted with bortezomib treatment.

Comment & Response 
Georgios Tsivgoulis, MD; Aristeidis H. Katsanos, MD; Andrei V. Alexandrov, MD

In Reply We thank Charidimou for reading our recently published article1 in JAMA Neurology on the risk for symptomatic intracerebral hemorrhage after intravenous thrombolysis (IVT) in patients with acute ischemic stroke (AIS) and high cerebral microbleed (CMB) burden on pre-IVT magnetic resonance imaging (MRI) screening,1 and ...

Comment & Response 
Andreas Charidimou, MD, MSc (Clinical Neurology), PhD

To the Editor I read with interest the article by Tsivgoulis et al1 in JAMA Neurology on cerebral microbleeds (CMBs) and the risk for symptomatic intracerebral hemorrhage (ICH) after intravenous thrombolysis for acute stroke, as well as the accompanying Editorial by Fisher.2 This work follows and ...

Editorial 
Joseph F. Quinn, MD

Numerous epidemiologic studies suggest that dietary consumption of fish or of ω-3 fatty acids (the putative “active ingredient” in fish) may reduce the risk of late-life dementia including Alzheimer disease (AD). However, clinical trials have failed to demonstrate disease-modifying effects in mild to moderate AD,1,2...

Original Investigation 
Reinier C. van Houwelingen, MD; Gert-Jan Luijckx, MD, PhD; Aryan Mazuri, MD; Reinoud P. H. Bokkers, MD, PhD; Omid S. Eshghi, MD; Maarten Uyttenboogaart, MD, PhD
Includes: Supplemental Content

Importance  After the many positive results in thrombectomy trials in ischemic stroke of the anterior circulation, the question arises whether these positive results also apply to the patient with basilar artery occlusion (BAO).

Objective  To report up-to-date outcome data of intra-arterial (IA) treatment in patients with ...

Original Investigation 
Hussein N. Yassine, MD; Qingru Feng, MSc; Ida Azizkhanian, MSc; Varun Rawat, PhD; Katherine Castor, PhD; Alfred N. Fonteh, PhD; Michael G. Harrington, MB, ChB; Ling Zheng, PhD; Bruce R. Reed, PhD; Charles DeCarli, MD; William J. Jagust, MD; Helena C. Chui, MD

Importance  Higher dietary intake of the essential fatty acid docosahexaenoic (DHA) has been associated with better cognitive performance in several epidemiological studies. Animal and in vitro studies also indicate that DHA prevents amyloid deposition in the brain.

Objective  To determine the association between serum DHA levels, ...

Editorial: Do ω-3 Fatty Acids Regulate Cerebral β Amyloid?; Joseph F. Quinn, MD
Images in Neurology 
Antonio Cruz-Culebras, MD; Rocío Vera, MD, PhD; Juan Martinez San Millan, MD

This case report describes the clinical and imaging features of a man in his 60s who had occlusion of a single pericallosal artery causing

bilateral corpus callosum infarction.

Comment & Response 
Qinghua Jiang, PhD; Yang Hu, PhD; Guiyou Liu, PhD

To the Editor We read with interest the study from Yokoyama et al.1 In this study, Yokoyama et al1 investigated the genetic overlap between Alzheimer disease and immune-mediated diseases including Crohn disease, ulcerative colitis, rheumatoid arthritis, type 1 diabetes, celiac disease, and psoriasis using 7 genome-wide ...

Comment & Response 
Jennifer S. Yokoyama, PhD; Rahul S. Desikan, MD, PhD

In Reply We appreciate the interest of Jiang et al and the research community in our work examining genetic overlap between Alzheimer disease (AD) and autoimmune disease. As we noted in our article,1 given the extensive linkage disequilibrium structure of regions, such as the HLA on chromosome ...

Viewpoint 
Lyell K. Jones Jr, MD

This Viewpoint discusses how the US health care system will transition from volume-based to value-based payment and care under the Medicare Access and Children’s Health Insurance Program Reauthorization Act of 2015.

Editorial 
Jill Sergesketter Butler, PhD; Marek Napierala, PhD

The use of short, synthetic nucleic acids as potential therapeutics was proposed more than 3 decades ago. However, improvements in the design and synthesis of nucleic acids have recently piqued the interest of researchers and physicians searching for alternative approaches for treating diseases that do not conform to ...

Sign in

Purchase Options

• Subscribe to the journal
• Rent this article ?

A free personal account provides

• Free current issues on The JAMA Network Reader
• Free quizzes on The JAMA Network Challenge
• Commenting and personalized alerts